Recombinant HLA-A Cell Library for Precise Alloreactivity Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing HLA alloreactivity and peptide specificity of immunotherapeutic agents, such as BiTE molecules and engineered TCRs, are inadequate and rely heavily on B cell-specific peptide repertoires, lacking control and precision.
Innovation Solution
Development of a recombinant cell line with deletions in the TAP, CD3ε, and HLA-A genes, engineered to express specific HLA-A alleles, allowing for a controlled assessment of alloreactivity and peptide specificity using a library of recombinant cells in conjunction with T cells and immunotherapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If B cell-specific peptide repertoires are used for screening HLA alloreactivity, then alloreactivity assessment can be performed, but the system lacks control and precision
Solution Approach 1:
The patent divides the complex B cell repertoire into individual, controlled recombinant cell lines, each expressing a specific HLA-A allele. This segmentation allows precise control over which HLA allele is presented and eliminates the variability inherent in using diverse B cell repertoires, thereby improving both precision and reliability of alloreactivity assessment.
Solution Approach 2:
The patent systematically varies the HLA-A allele parameter across different recombinant cell lines while keeping other factors constant. This controlled parameter change enables precise measurement of alloreactivity for each specific HLA allele, transforming an uncontrolled biological system into a controllable experimental system with improved reliability.
2Adaptability or versatility
If a diverse array of B lymphoblastoid cell lines is used to represent HLA class I allotypic diversity, then screening coverage is improved, but system complexity increases
Solution Approach 1:
Instead of using a diverse array of different cell line types, the patent segments the diversity into a standardized set of recombinant cell lines, each representing a specific HLA-A allele. This approach maintains comprehensive coverage of HLA allotypic diversity while using a uniform cell line platform, thereby reducing system complexity.
Solution Approach 2:
The patent creates a universal screening platform where recombinant cell lines with different HLA-A alleles serve the same functional purpose. These standardized cell lines can be used across multiple experiments and applications, providing versatility in HLA coverage while simplifying the overall system through standardization.
3Ease of manufacture
If standard B cell-based screening methods are used, then existing protocols can be maintained, but the ability to control peptide specificity is limited
Solution Approach 1:
The patent performs preliminary action by pre-engineering the recombinant cell lines with specific HLA-A alleles and peptide presentation capabilities before the actual screening experiment. This preliminary preparation allows precise control over peptide specificity during the assay while maintaining the ease of using standardized protocols, as the cell lines are already optimized for specific HLA alleles.
Data Source
AI summary
Provided herein is a recombinant cell comprising a deletion of a gene encoding a transporter associated with antigen processing (TAP) protein and mutations in the CD3 epsilon gene and an HLA-A gene. Also provided are systems and methods for screening for alloreactivity and specificity of an immunotherapeutic agent, such as a bispecific T cell engager or an engineered T cell receptor (TCR).